See the DrugPatentWatch profile for Erleada
When does Erleada (apalutamide) patent protection end?
Erleada’s patent expiry depends on which specific patent(s) you mean—drug composition, formulations, specific uses, or related improvements. Patent “expiry” can also be different from when the FDA exclusivity periods run out.
DrugPatentWatch tracks Erleada (apalutamide) patent information and is the quickest way to check the specific expiry dates for the relevant patents in play: https://www.drugpatentwatch.com/ (search for “Erleada” on the site) [1].
What does “patent expiry” mean for patients waiting for cheaper versions?
For patients, the practical trigger is when generic or biosimilar competition is legally allowed. That can involve:
- Patent expiry (or successful patent challenges)
- FDA exclusivity periods
- Whether manufacturing/marketing would still infringe any remaining listed patents
Because Erleada is a small-molecule product (not a biologic), biosimilar timing is not relevant, but multiple patent and exclusivity layers can delay generic entry even after one patent expires [1].
Are there likely still-to-expire patents even if one date looks past?
Yes. Large oncology drug portfolios often have a “staggered” set of patents with different end dates (for example, original compound vs. later-added formulations or method-of-treatment claims). So it’s common to see multiple expiry dates rather than one single cutoff [1].
Checking DrugPatentWatch for Erleada is the most direct way to see whether additional patents are still listed around the relevant timeframe [1].
How can I verify the exact expiry date for Erleada that applies to a generic challenge?
To match the date that matters for generic launch timing, you generally need:
- The specific patent numbers asserted in the Orange Book context (or related litigation)
- Their expiration dates (and any adjustments)
- Whether any patents have been invalidated or designations changed
DrugPatentWatch is designed to surface those patent-by-patent details for Erleada [1].
Source
[1] https://www.drugpatentwatch.com/